Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review

European Archives of Psychiatry and Clinical Neuroscience

Volumn 256, Issue 1, 2006, Pages 1-16

  Möller, Hans Jürgen ^a   Grunze, Heinz ^a   Broich, Karl ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Federal Institute for Drugs and Medical Devices Bundesinstitut für Arzneimittel und Medizinprodukte   (Germany)

Author keywords

Acute bipolar depression; Antidepressants; Lamotrigine; Mood stabilizers; Second generation antipsychotics

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; IDAZOXAN; IMIPRAMINE; LAMOTRIGINE; LITHIUM CHLORIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADD ON THERAPY; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONCEPT FORMATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HAMILTON SCALE; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MANIA; MEDICAL DECISION MAKING; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RAPID CYCLING BIPOLAR DISORDER; REVIEW; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT INDICATION; WITHDRAWAL SYNDROME;

ACUTE DISEASE; AFFECT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG APPROVAL; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33344474968     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-005-0591-9     Document Type: Review

References (90)

1. Adli M, Bschor T, Canata B, Dopfmer S, Bauer M (1998) Lithium in the treatment of acute depression. Fortschr Neurol Psychiatr 66:435-441
2. Altshuler L, Kiriakos L, Calcagno J, Goodman R, Gitlin M, Frye M, Mintz J (2001) The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 62:612-616
3. Altshuler L, Suppes T, Black D, Nolen WA, Keck P-EJ, Frye MA, McElroy S, Kupka R, Grunze H, Walden J, et al. (2003) Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 160:1252-1262
4. th ed., DSM-IV. APA, Washington DC
5. American Psychiatric Association (APA) (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1-50
6. Andersen UA, Andersen M, Rosholm JU, Gram LF (2001) Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand 104:458-465
7. Angst J, Angst F, Gerber-Werder R, Gamma A (2005) Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res (In Press)
8. Ascher J, Barnett S, Batey S (2001) Safety and tolerability of lamotrigine in controlled mood disorder trials. Presentation at the Annual Meeting of the American Psychiatric Association, New Orleans, USA, 5-10 May 2001
9. Ballenger JC, Post RM (1980) Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137:782-790
10. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5-43
11. Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell BJ (1999) Clinical practice guidelines for bipolar disorder from the department of veterans affairs. J Clin Psychiatry 60:9-21
12. Bauer MS, Mitchner L (2004) What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 161:3-18
13. Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M (1993) A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 88:434-439
14. Bottlender R, Jager M, Strauss A, Möller H-J (2000) Suicidality in bipolar compared to unipolar depressed inpatients. Eur Arch Psychiatry Clin Neurosci 250:257-261
15. Bottlender R, Rudolf D, Strauß A, Möller HJ (2001) Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Aff Disord 63:79-83
16. Bottlender R, Rudolf D, Jäger M, Strauss A, Möller HJ (2002) Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Results from a case control study. Eur Psychiatry 17:1-6
17. Bowden CL (2002) Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother 3:1513-1519
18. th ECNP, Prague, 20-24 September 2003
19. Calabrese JR, Delucchi GA (1990) Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 147:431-434
20. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79-88
21. Calabrese J, MacFadden W, McCoy R, Minkwitz M, Wilson E, Mullen J (2004a) Double-blind, placebo-controlled study of quetiapine in bipolar depression. Abstract presented at APA 2004, NYC, USA
22. Calabrese JR, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, Young AH (2004b) International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry 65:571-579
23. Cohn JB, Collins G, Ashbrook E, Wernicke JF (1989) A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 4:313-322
24. CPMP (2001) CPMP/EWP/567/98. Note for guidance on clinical evaluation of medicinal products in the treatment and prevention of bipolar disorder. http://www.emea.eu.int/pdfs/human/ewp/056798en
25. CPMP (2002) CPMP/EWP/518/97, Rev. 1. Note for guidance on clinical evaluation of medicinal products in the treatment of depression. http://www.edea.eu.int/pdfs/human/ewp/051897en
26. De Wilde JE, Doogan DP (1982) Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 4:249-259
27. Dilsaver SC, Swann SC, Chen YW, Shoaib A, Joe B, Krajewski KJ, Gruber N, Tsai Y (1996) Treatment of bipolar depression with carbamazepine: results of an open study. Biol Psychiatry 40:935-937
28. Fieve RR, Platman SR, Plutchik RR (1968) The use of lithium in affective disorders. I. Acute endogenous depression. Am J Psychiatry 125:487-491
29. Frances AJ, Docherty JP, Kahn DA (1996) The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 57(Suppl 12A):3-88
30. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL (1998) The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 59(Suppl 4):73-79
31. Freyhan FA (1957) Psychomotility, extrapyramidal syndrome and mode of action of neuroleptic therapies, chlorpromazine, reserpine and prochlorperazine. Nervenarzt 28:504-509
32. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM (2000) A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20:607-614
33. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004) Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161:1537-1547
34. Goodwin GM (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17:149-173
35. Goodwin GM, Nolen WA (1997) Treatment of bipolar depressive mood disorders: algorithms for pharmacotherapy. Int J Psychiatry Clin Prac 1(Suppl 1):S9-S12
36. Grossman F, Potter WZ, Brown EA, Maislin G (1999) A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord 56:237-243
37. Grunze H, Möller HJ (2003) The use of atypical antipsychotics in bipolar spectrum disorders. Indian J Psychiatry 45:10-15
38. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ (2002) World Federation of Societies of Biological Psychiary (WFSBP) guidelines for biological treatment of bipolar diorders, Part I: Treatment of bipolar depression. World J Biol Psychiatry 3:115-124
39. Hahn CG, Gyulai L, Baldassano CF, Lenox RH (2004) The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry 65:791-804
40. Himmelhoch JM, Fuchs CZ, Symons BJ (1982) A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 170:628-634
41. Himmelhoch JM, Thase ME, Mallinger AG, Houck P (1991) Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148:910-916
42. Hirschfeld RMA, Clayton PJ, Cohen I, Fawcett J, Keck P, McClellan J, McElroy S, Post R, Satloff A (1994) Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 151:1-36
43. Hirschfeld RMA, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, et al. (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63:826-837
44. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59:530-537
45. Kasper S, Haushofer M, Zapotoczky HG, Aschauer H, Wolf R, Hinterhuber H, Bonelli M, Wuschitz A (1999) Konsensus-Statement: Diagnostik und Therapie der bipolaren Störung. Neuropsychiatrie 13:100-108
46. Keller MB (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289:3152-3160
47. Khan A, Brown WA (2001) The placebo enigma in antidepressant clinical trials. J Clin Psychopharmacol 21:123-125
48. Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311-317
49. Khan A, Khan SR, Leventhal RM, Brown WA (2001) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 4:113-118
50. Khan A, Khan S, Brown WA (2002a) Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 5:193-197
51. Khan A, Leventhal RM, Khan SR, Brown WA (2002b) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22:40-45
52. Khan A, Khan SR, Walens G, Kolts R, Giller EL (2003) Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 28:552-557
53. Khan MC, Wickham EA, Reed JV (1987) Lithium versus placebo in acute depression: a clinical trial. Int Clin Psychopharmacol 2:47-54
54. Kusumakar V, Yatham LN, Haslam DR, Parikh SV, Matte R, Silverstone PH, Sharma V (1997) Treatment of mania, mixed state, and rapid cycling. Can J Psychiatry 42(Suppl 2):79S-86S
55. Laakman G, Blaschke D, Hippius H, Messerer D (1986) Alprazolam versus amitriptyline in the treatment of depressed out-patients: a randomized double-blind trial. In: Lader HL, Davies HC (eds) Drug treatment of neurotic disorders. Edinburgh London Melbourne New York, Churchill Livingstone, pp 129-136
56. Lambert PA (1984) Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HE, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Amsterdam, Elsevier Science Publishers, pp 33-44
57. McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J (2004) A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 65:204-210
58. Mendels J (1976) Lithium in the treatment of depression. Am J Psychiatry 133:373-378
59. Mendlewicz J, Youdim MB (1980) Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J Affect Disord 2:137-146
60. Möller HJ (1992) Klinische Prüfstudien. Allgemeine Grundlagen der Pharmakopsychiatrie. Riederer P, Laux G, and Pöldinger W Neuro-Psychopharmaka. 1. Wien New York, Springer, pp 177-199
61. Möller HJ (2005a) Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci 255:83-93
62. Möller HJ (2005b) Antipsychotic and antidepressive effects of second generation antipsychotics - two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci (In Press)
63. Möller H-J, Grunze H (2000) Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 250:57-68
64. Möller HJ, Bottlender R, Grunze H, Strauss A, Wittmann J (2001) Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Aff Disord 67:141-146
65. Montgomery DB (2001) ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 11:79-88
66. Montgomery SA, Lecrubier Y (1999) Is severe depression a separate indication? ECNP Consensus Meeting September 20:1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 9:259-264
67. Motohashi N (1999) Algorithms for the pharmacotherapy of bipolar disorder. Psychiatry and Clinical Neurosciences 53:S41-S44
68. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD (2001) Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 158:906-912
69. Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J (2002) Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 63:337-344
70. Post RM, Uhde TW, Roy BP, Joffe RT (1986) Antidepressant effects of carbamazepine. Am J Psychiatry 143:29-34
71. Post RM, Leverich GS, Denicoff KD, Frye MA, Kimbrell TA, Dunn R (1997) Alternative approaches to refractory depression in bipolar illness. Depress Anxiety 5:175-189
72. Roth BL, Sheffler D, Potkin SG (2003) Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin Neurosci Res 3:108-117
73. Sachs GS (1996) Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 16:32S-47S
74. Sachs GS (2005) What is a mood stabilizer? Clin Appro in Bipolar Disorders 4:3
75. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF (1994) A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 55:391-393
76. Sachs GS, Koslow CL, Ghaemi SN (2000a) The treatment of bipolar depression. Bipolar Disord 2:256-260
77. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP (2000b) The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med Spec 1-104
78. Sachs G, Collins MA, Altshuler L, Ketter T, Suppes T, Rasgon N, Frye M, Wozniak P, Tracy K, Sommerville KW (2002) Divalproex sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus and Proceedings Summary
79. Severus WE, Grunze H, Kleindienst N, Möller HJ (2005) The efficacy of lithium as maintenance treatment in bipolar disorder in the light of new approval studies. Clin Psychopharm (Submitted)
80. Silverstone T (2001) Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand 104:104-109
81. Souza FG, Goodwin GM (1991) Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 158:666-675
82. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van Strik R, Broekmans AW (2001) Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11:173-180
83. Svestka J, Deskova E, Rysanek R, Nahunek K (1991) Antiepileptics in the treatment of endogenous depression. Proceedings IVth World Congress of Biological Psychiatry
84. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, et al. (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079-1088
85. Walden J, Grunze H, Schlösser S, Berger M, Bergmann A, Bräunig P, Dose M, Emrich HE, Gastpar M, Greil W, et al. (1999) Empfehlungen für die Behandlung bipolarer affektiver Störungen (Recommendations for the treatment of bipolar affective disorder). Psychopharmakotherapie 6:115-123
86. Winsberg ME, DeGolia SG, Strong CM, Ketter TA (2001) Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 67:207-212
87. Yatham LN, Kusumakar V, Parikh SV, Haslam DR, Matte R, Sharma V, Kennedy S (1997) Bipolar depression: treatment options. Can J Psychiatry 42(Suppl 2):87S-91S
88. Young LT (2004) What exactly is a mood stabilizer? J Psychiatry Neurosci 29:87-88
89. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I (2000) Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157:124-126
90. Zornberg GL, Pope Jr HG (1993) Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 13:397-408